Business and Economy >>>
Biotechnology and Pharmaceuticals >>>
Biomedical Engineering >>
Company:
Biogen Idec Inc
Services:
In November 2003, Biogen Idec Inc. (NASDAQ: BIIB) was formed from the merger of two of the world’s leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. This combination has resulted in a fusion of complementary strengths in therapeutic focus, research and development capabilities, manufacturing expertise, global infrastructure and financial position. Biogen Idec intends to continue its growth through discovery, development and commercialization of its own innovative products and through strategic alliances as the preferred partner for biologics development, manufacturing and marketing.
Biogen Idec is dedicated to pursuing the creativity of science. The company’s products and development programs address a variety of key medical needs in the areas of oncology, neurology, dermatology and rheumatology.
Scientific excellence that achieves new standards of care drives the company’s work. Biogen Idec invested $684 million in research and development in 2004, and has 1,000 R&D employees, including approximately 400 in discovery research. The company has a pipeline of 9 products in clinical development.
Two blockbuster drugs, each with current annual net sales of more than $1 billion, lead Biogen Idec’s product lineup. RITUXAN® (rituximab) was discovered by Biogen Idec for the treatment of certain B-cell non-Hodgkin’s lymphomas (NHL), and the company co-promotes the product in the United States with Genentech, Inc. AVONEX® (Interferon beta 1-a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). In 2002, AVONEX became the first MS product to achieve $1 billion in sales.
In addition, the company has two other marketed products ZEVALIN® (Ibritumomab tiuxetan) and AMEVIVE® (alefacept) which were launched in 2002 and 2003 respectively. In November 2004, Biogen Idec, in partnership with Elan Corporation plc., received FDA approval for TYSABRI® (natalizumab). Currently, the companies have voluntarily suspended the marketing of TYSABRI. In addition, the companies have suspended dosing in all clinical trials. Please click here to open Dear Healthcare Professional Letter Regarding TYSABRI®.
Biogen Idec also has products in Phase III clinical trials: RITUXAN, in partnership with Genentech and F. Hoffman-LaRoche, for the treatment of rheumatoid arthritis and other cancer indications. BG-12, an oral fumarate licensed from Fumapharm AG, is in Phase III trials for psoriasis in Europe (for submission in Germany).
In addition to Biogen Idec’s promising portfolio of drug candidates, the company’s capabilities and capacity for protein manufacturing are also world-class in quality and scale. The company is one of a handful of biotechnology companies that has three licensed and dedicated biological bulk-manufacturing facilities, including its large-scale manufacturing plant in Research Triangle Park, NC, which is one of the world’s largest cell culture facilities. Biogen Idec has sufficient commercial manufacturing capacity for its own pipeline, as well as potential partners’ products.
Biogen Idec is headquartered in Cambridge, MA. The company maintains centers of excellence in San Diego, CA and Cambridge focused on oncology and immunology. The company has additional offices in Canada, Australia, Japan and throughout Europe, including international headquarters in Zug, Switzerland. The company currently employs approximately 4,000 people worldwide.
Contact Details:
14 Cambridge Center
Cambridge, MA 02142
TEL: 617-679-2000
W:
http://www.idecpharm.com
Not found what you are looking for? then
click here for more results on
bio-technology
![]() |
